Please login to the form below
Cushing disease
This page shows the latest Cushing disease news and features for those working in and with pharma, biotech and healthcare.
New data for Recordati’s Isturisa reinforces benefit in Cushing’s disease
Recordati Rare Disease has revealed new data from a phase 3 trial of its Cushing’s disease treatment Isturisa. ... This data adds to the robust body of evidence supporting Isturisa as an effective and well-tolerated treatment for patients with
Latest news
-
FDA approves Recordati’s Cushing disease drug Isturisa
Important new treatment option for patients with rare disorder. Italy’s Recordati has claimed FDA approval for Isturisa, an oral drug for adult Cushing’s disease patients who can’t be ... Cushing’s disease is a rare disorder that occurs when the
-
Novartis' acromegaly therapy cleared by FDA
It leads to an increase in bone size, particularly those in the hands, feet and face, alongside other complications such as diabetes, arthritis, kidney disease and cancer. ... A short-acting formulation of Signifor that requires twice-daily dosing is
-
Novartis gets EU nod for rare disease drug Signifor
Signifor (pasireotide) was first approved in Europe in 2012 as a twice-daily subcutaneous injection for Cushing's disease, but the new depot formulation - called Signifor LAR - requires just one intramuscular ... It is also testing the new formulation
-
Novartis plans filings for acromegaly candidate
A twice-daily formulation of Signifor (pasireotide) is already on the market for the treatment of Cushing's disease, but the latest study assessed a once-monthly intramuscular formulation - called Signifor ... The company has already filed for approval
-
Novartis cancer chief Hoppenot leaves for top job at Incyte
During his time at the helm of Novartis' cancer division Hoppenot presided over the launch of two new cancer therapies, Jakavi for myelofibrosis in 2011 and Signifor (pasireotide) for Cushing's ... disease in 2012, while rolling out new indications for
More from news
Approximately 1 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Pharma deals during April 2014
Jakavi (rare bone marrow disorder); Signifor (Cushing's disease) plus 16 products in 24 pivotal trials.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
emotive adds to medical team with new Scientific Lead and Associate Medical Writer
in rare diseases such as Gaucher disease and Cushing’s disease and in hepatitis C. She also has experience in cardiovascular disease, haematology and infectious diseases. ... emotive is an award-winning healthcare communications agency working
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Editorial Team Leader, Medical Communications, Oxford
-
Competitive Salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
-
Head of Copy
-
£ competitive
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Graduate Business Analyst, Healthcare Communications – Pharma/ S...
-
Highly competitive salary
- AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients
- Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results
- Why pharma must get smart in its approach to customer engagement
- GSK appoint Tony Wood as chief scientific officer
- Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
- Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis
- Lucid Group Welcomes a New Cohort of Graduates into its Futures Academy
- Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19
- SMC approves Parkinson’s disease treatment Ongentys
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- Home or away: where next for pharmaceutical symposia?
- PM announces plans to lift England’s COVID-19 restrictions
- Why pharma must get smart in its approach to customer engagement
- AstraZeneca's Enhertu receives FDA grant for priority review
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
- NAVIGATING 2022: THE FIVE CRITICAL SHIFTS PHARMA NEEDS TO EMBRACE
- Amgen’s Lumykras receives conditional marketing authorisation from EC
- SMC approves Parkinson’s disease treatment Ongentys
PMHub
Origins Insights
Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...
Latest intelligence
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
- Cervical Cancer Prevention Month
- In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
- 6 critical success factors for flawless execution of a rapid first commercial launch
- Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
